Kamada (NASDAQ:KMDA) Receives New Coverage from Analysts at StockNews.com

StockNews.com began coverage on shares of Kamada (NASDAQ:KMDA) in a research note issued to investors on Thursday. The brokerage issued a buy rating on the biotechnology company’s stock.

Separately, HC Wainwright reissued a buy rating and set a $11.00 target price on shares of Kamada in a research note on Thursday, May 9th.

Kamada Stock Performance

KMDA stock opened at $5.30 on Thursday. The business’s 50-day moving average is $5.43 and its two-hundred day moving average is $5.60. Kamada has a fifty-two week low of $4.08 and a fifty-two week high of $6.53. The company has a market cap of $304.64 million, a price-to-earnings ratio of 23.04 and a beta of 1.05.

Kamada (NASDAQ:KMDA) last posted its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported $0.09 EPS for the quarter, topping the consensus estimate of $0.05 by $0.04. Kamada had a return on equity of 5.50% and a net margin of 8.33%. The firm had revenue of $36.43 million for the quarter, compared to the consensus estimate of $37.71 million. Equities analysts predict that Kamada will post 0.23 earnings per share for the current year.

Institutional Trading of Kamada

Several institutional investors and hedge funds have recently added to or reduced their stakes in KMDA. EWA LLC bought a new stake in Kamada during the 4th quarter valued at approximately $68,000. Y.D. More Investments Ltd grew its holdings in Kamada by 107.1% during the 4th quarter. Y.D. More Investments Ltd now owns 29,002 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 15,000 shares in the last quarter. Calton & Associates Inc. purchased a new position in Kamada during the 4th quarter valued at approximately $111,000. Aristides Capital LLC grew its holdings in Kamada by 41.6% during the 4th quarter. Aristides Capital LLC now owns 56,635 shares of the biotechnology company’s stock valued at $347,000 after buying an additional 16,635 shares in the last quarter. Finally, Vanguard Group Inc. grew its holdings in Kamada by 8.2% during the 1st quarter. Vanguard Group Inc. now owns 1,325,026 shares of the biotechnology company’s stock valued at $7,433,000 after buying an additional 100,800 shares in the last quarter. Institutional investors own 20.38% of the company’s stock.

Kamada Company Profile

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.